Therefore, clinical translation of our finding that a highly selective A3AR agonist can prevent and reverse chemotherapy-induced cognitive decline, sensorimotor deficits and peripheral neuropathy should be feasible. The gene discussed is ADORA3; the disease is peripheral neuropathy.